BioSpace News Archive

The DSMB endorsed the use of mRNA-1345 for the Phase III ConquerRSV study following positive preliminary Phase II data that demonstrates the vaccine’s safety profile.

Public health officials begin to think we’ve turned the corner on the pandemic as new global cases drop 21% last week, the third consecutive week numbers and deaths have declined.

Plexium raised millions for its multi-year research collaboration and license deal with Amgen to identify novel targeted protein degradation therapeutics.

Studies of Relmada’s drug, esmethadone, showed the drug had lower human abuse potential when compared to ketamine. Here are the results of this study.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.

Research on obesity is essential, as it can lead to serious health consequences. Researchers are now turning to the immune system for answers about the condition.

AstraZeneca and Sanofi secured accelerated authorization for respiratory syncytial virus (RSV) antibody nirsevimab from the European Medicines Agency.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021.

Arena Pharmaceuticals, Inc. provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.